Structure Therapeutics (Structure Therapeutics) Total Stockholders Equity : $429.82 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Structure Therapeutics Total Stockholders Equity?

Structure Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $429.82 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Structure Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $9.22. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Structure Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.01.

Structure Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Structure Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Structure Therapeutics Total Stockholders Equity Chart

Structure Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

-22.47

-64.74

-115.14

452.97

Structure Therapeutics Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial							236.35	214.41	192.96	452.97	429.82

Structure Therapeutics (NAS:GPCR) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Structure Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(429.818	-	0)	/	46.6183
	=	9.22

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Structure Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.6	+	3.525)	/	429.818
	=	0.01

Structure Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Structure Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Structure Therapeutics (Structure Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Structure Therapeutics Inc (NAS:GPCR) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

611 Gateway Boulevard, Suite 223, South San Francisco, CA, USA, 94080

Website

https://www.structuretx.com

Structure Therapeutics Inc is a clinical-stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.

Executives

Ted W Love	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Trading Fund Os Lp	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Melita Sun Jung	officer: Chief Business Officer	C/O STRUCTURE THERAPEUTICS INC., SOUTH SAN FRANCISCO CA 94080
Yingli Ma	officer: Chief Technology Officer	C/O STRUCTURE THERAPEUTICS INC., 611 GATEWAY BLVD., SUITE 223, SOUTH SAN FRANCISCO CA 94080
Joanne Waldstreicher	director	C/O STRUCTURE THERAPEUTICS INC., 611 GATEWAY BLVD, SUITE 223, SOUTH SAN FRANCISCO CA 94080
Jun Yoon	officer: Chief Financial Officer	C/O STRUCTURE THERAPEUTICS INC., 611 GATEWAY BLVD, SUITE 223, SOUTH SAN FRANCISCO CA 94080